Northland Securities analyst Carl Byrnes maintained a Buy rating on vTv Therapeutics (VTVT) today and set a price target of $8. The company’s shares opened today at $1.89.
Byrnes said:
“We note that diabetic ketoacidosis has been an issue w/ Lexicon/Sanofi’s Zynguista (sotagliflozin) that received a CRL in March 2019, and AstraZeneca’s FARXIGA (dapagliflozin) which is NOT approved for treating type 1 diabetes.”
According to TipRanks.com, Byrnes has currently no stars on a ranking scale of 0-5 stars, with an average return of -9.2% and a 25.5% success rate. Byrnes covers the Healthcare sector, focusing on stocks such as Opiant Pharmaceuticals Inc, Aridis Pharmaceuticals Inc, and Adamas Pharmaceuticals.
Currently, the analyst consensus on vTv Therapeutics is a Moderate Buy with an average price target of $6.50, representing a 243.9% upside. In a report issued on May 30, H.C. Wainwright also initiated coverage with a Buy rating on the stock with a $5 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $6.09 and a one-year low of $0.68. Currently, vTv Therapeutics has an average volume of 803.4K.
Based on the recent corporate insider activity of 15 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of VTVT in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
vTv Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. Its products target the treatment of central nervous system disorders, diabetes and metabolic disorders, inflammation, and cancer.
